• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
CohBar, Inc. (CWBR) Stock Price, News & Analysis

CohBar, Inc. (CWBR) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.51

$0.01

(2.6%)

Day's range
$0.51
Day's range
$0.51
50-day range
$0.43
Day's range
$0.6
  • Country: US
  • ISIN: US19249J3077
52 wk range
$0
Day's range
$1.1
  • CEO: Dr. Pinchas Cohen Dean, M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -13.83
  • Piotroski Score 1.00
  • Grade Buy
  • Symbol (CWBR)
  • Company CohBar, Inc.
  • Price $0.51
  • Changes Percentage (2.6%)
  • Change $0.01
  • Day Low $0.51
  • Day High $0.51
  • Year High $1.10

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/21/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$4.37
  • Trailing P/E Ratio -0.18
  • Forward P/E Ratio -0.18
  • P/E Growth -0.18
  • Net Income $-11,962,119

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

CohBar, Inc. Frequently Asked Questions

  • What is the CohBar, Inc. stock price today?

    Today's price of CohBar, Inc. is $0.51 — it has increased by +2.6% in the past 24 hours. Watch CohBar, Inc. stock price performance more closely on the chart.

  • Does CohBar, Inc. release reports?

    Yes, you can track CohBar, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the CohBar, Inc. stock forecast?

    Watch the CohBar, Inc. chart and read a more detailed CohBar, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is CohBar, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by CohBar, Inc. stock ticker.

  • How to buy CohBar, Inc. stocks?

    Like other stocks, CWBR shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is CohBar, Inc.'s EBITDA?

    CohBar, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in CohBar, Inc.’s financial statements.

  • What is the CohBar, Inc.'s net income ratio for the financial year 2022?

    The net income ratio for the financial year 2022 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in CohBar, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including CohBar, Inc.'s financials relevant news, and technical analysis. CohBar, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for CohBar, Inc. stock currently indicates a “sell” signal. For more insights, review CohBar, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.